Screener
Arvinas ARVN Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arvinas in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Arvinas’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 5:18 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033669
| (dollars in millions) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Non program-specific external expense | 9.2 | 13.9 |
| Compensation and related personnel expense(including stock-based compensation) | 21.3 | 36.9 |
| Other research and development expense | 2.4 | 3.1 |
| Total research and development expense | 60.3 | 90.8 |
| General and administrative expense | 19.1 | 26.6 |
| Other segment expense, net (**) | 0.1 | — |
| Income tax expense | 0.1 | 0.2 |
| Plus: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arvinas's business segments — R&D?
- Arvinas (ARVN) reported business segments — R&D of $60.3M in Q1 2026.
- How has Arvinas's business segments — R&D changed year-over-year?
- Arvinas's business segments — R&D decreased by 33.6% year-over-year, from $90.8M to $60.3M.
- What is the long-term trend for Arvinas's business segments — R&D?
- Over 3 years (2022 to 2025), Arvinas's business segments — R&D has grown at a -3.3% compound annual growth rate (CAGR), from $315M to $285.2M.
- What does business segments — R&D mean?
- This represents the total investment made by the segment into the discovery and development of new therapeutic candidates. It is a critical measure of the company's commitment to innovation and its long-term pipeline potential.
Ask your AI about Arvinas's business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude